You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Guidelines and links

British Thoracic Society / Scottish Intercollegiate Guidelines Network, UK (BTS / SIGN) www.brit-thoracic.org.uk (2014)

  • Children and adults with mild and moderate exacerbations of Asthma should be treated by bronchodilators given from a pMDI + Spacer/Holding Chamber with doses titrated according to clinical response
  • Use Spacer/Holding Chamber with facemask for children aged 0 to 5 years
  • Use pMDI + Spacer/Holding Chamber in children 5-12 years of age receiving corticosteroids

National Institute for Clinical Excellence, UK (NICE) www.nice.org.uk (2015)

  • Spacer/Holding Chamber recommended with a facemask where necessary for both corticosteroids and bronchodilators (Children under 5)
  • A press and breathe pMDI used with an appropriate Spacer/Holding Chamber is first choice for corticosteroids (Children aged 5-15 years)

Global Initiative on Asthma (GINA) www.Ginasthma.org (2014)

  • pMDI + dedicated Spacer/Holding Chamber with facemask is the recommended inhaler choice for children 4 years of age and younger
  • pMDI + dedicated Spacer/Holding Chamber with mouthpiece is the recommended inhaler choice for children between 4 and 5 years of age

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.

AeroChamber Plus is manufactured by Trudell Medical International. Distributed in the UK by GlaxoSmithKline.